{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-000907","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2026-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.613558+00:00","generated_at":"2026-05-16T11:48:44.713270+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Atara amends Pierre Fabre deal: cuts regulatory milestones by $9M, adds $15M commercial milestone","bullets":["Regulatory milestone payments from Pierre Fabre reduced from $40M to $31M (decrease of $9M).","New $15M commercial milestone payable upon Product Net Sales exceeding a confidential threshold.","Amendment also modifies other payment sections (redacted) in the commercialization agreement.","Atara submitted BLA for tab-cel (EBV+ PTLD) to FDA in May 2024; Pierre Fabre has exclusive U.S. commercialization rights.","Agreement originally dated October 2023; fourth amendment effective December 30, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-000907","json":"https://secwatch.observer/filing/0001193125-26-000907.json","markdown":"https://secwatch.observer/filing/0001193125-26-000907.md","text":"https://secwatch.observer/filing/0001193125-26-000907.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526000907/0001193125-26-000907-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526000907/d90230d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:48:44.713270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b67e2592dc267355e12c1eb7e4576e0783559472","claim":"Atara Biotherapeutics, Inc. amended Fourth Amendment with Pierre Fabre Medicament valued at from $40.0 million to $31.0 million (effective 2025-12-30).","evidence_excerpt":"Under the terms of the Amendment, the Company has agreed to reduce the aggregate amount of potential milestone payments payable by Pierre Fabre to the Company upon achieving certain regulatory milestones relating to the approval by the FDA of a BLA for tab-cel from $40.0 million to $31.0 million for the right to receive an additional $15.0 million potential milestone payment from Pierre Fabre to the Company upon achieving a certain commercial milestone.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526000907/0001193125-26-000907-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Pierre Fabre Medicament"},{"label":"Value","value":"from $40.0 million to $31.0 million"},{"label":"Effective","value":"2025-12-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}